Life Sciences

The 10 largest funds accounted for more than half of all capital raised, with industrial-focused Triton and Greenbriar among the winners

OpenAI has jumped into a category startup investors assumed it’d avoid. But they’re welcoming the move.

The world’s largest charitable organization looks to boost innovation through research body and startup builder BioInnovation Institute.

Although Q1 recorded the continent’s highest deal value to date, 2025 has since been a lackluster year for life sciences.

Lenders cut spreads and eased covenants for borrowers amid increased competition from other debt providers and pressure to deploy capital.

Less than a month into Q1, the sector has already raised more than half of Q4’s total deal value.

PE firms have increasingly been involved in funding drug development.

PE deal activity in the sector is riding tailwinds from M&A-friendly interest rate policies and GPs’ growing appetite for life sciences investments.

Even with the slowdown in dealmaking among European venture investors, VCs are demonstrating a relatively strong appetite for startups in the life sciences sector.

New Mountain Capital has agreed to acquire multiple business divisions of PerkinElmer, a life sciences and pharmaceutical company, for $2.45 billion, marking one of the largest PE deals within the sector in recent years

Apollo Global Management has agreed to take a minority stake in life sciences VC Sofinnova Partners.

The biotech has priced its IPO at $23 per share, raising roughly $604 million. We’ve put together a datagraphic of the company’s financials, key shareholders, valuation history and more.

Blackstone hasn’t been shy about secondaries deals in 2018. The firm plans to go even further with a wholesale takeover of Clarus, a life sciences investment firm.